Premium
Ex vivo IL‐15 replenishment augments bone marrow precursor cell‐mediated adaptive immunity via PI3K‐Akt pathway
Author(s) -
Zhang Li Xiao,
Chen Rui Ling,
Liao Xiao Yan,
You Xiang,
Gao Feng Guang
Publication year - 2020
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.1ma0220-337rr
Subject(s) - pi3k/akt/mtor pathway , protein kinase b , priming (agriculture) , acquired immune system , biology , ctl* , immune system , immunology , t cell , antigen presentation , cancer research , ex vivo , microbiology and biotechnology , in vivo , signal transduction , cd8 , botany , germination
This study tested the hypothesis that PI3K‐Akt activity contributes to the superior immune function of IL‐15‐administrated bone marrow precursor cells (BMPC). Our previous studies revealed that PI3K‐Akt play vital role in dendritic cells (DCs) cross‐presentation and DC‐based CTL priming. Despite the fact that IL‐15 serves multiple functions in its therapeutic potential for the induction and maintenance of T cell response, the exact role of PI3K‐Akt in IL‐15 increased adaptive immunity is still poorly understood. In this study, we demonstrated that ex vivo IL‐15 administration increased BMPC capability of antigen uptake and the expression of costimulatory molecules (such as CD80 and 4‐1BB(CD137) ligand [4‐1BBL]) and MHC class I molecule via PI3K‐Akt pathway. Importantly, PI3K‐Akt activity was not only necessary for IL‐15 augmented BMPC cross‐presentation and CTL priming, but also facilitated IL‐15 increased therapeutic potential of the cytolytic capacity and maintenance of BMPC‐activated T cells. Thus, these data suggested that PI3K‐Akt activity contribute to the superior immune function of IL‐15‐administrated BMPC and thereby might be therapeutic potential for adaptive immunity.